Navigation Links
Synthetic Biologics to Report 2016 Year End Operational Highlights and Financial Results on March 2, 2017
Date:2/21/2017

ROCKVILLE, Md., Feb. 21, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, intends to report operational highlights and financial results for the year ended December 31, 2016 on Thursday, March 2, 2017, and to host a conference call the same day at 4:30 p.m. EST. The dial-in information for the call is as follows:

U.S. (toll free): 1-888-347-5280
International: +1 412-902-4280

Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at https://www.webcaster4.com/Webcast/Page/1096/19873. An archived replay of the call will be available for approximately ninety (90) days at the same URL, https://www.webcaster4.com/Webcast/Page/1096/19873 beginning approximately one hour after the call's conclusion.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and (2) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), antibiotic-associated diarrhea (AAD) and the emergence of antimicrobial-resistance (AMR). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.   

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-2016-year-end-operational-highlights-and-financial-results-on-march-2-2017-300410841.html


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Synthetic Biology: Global Markets - Research and Markets
2. Synthetic Biologics to Present at the 2017 BIO CEO & Investor Conference
3. Ginkgo Bioworks Acquires Leading Synthetic DNA Provider Gen9
4. Synthetic Genomics Appoints Tina Nova, Ph.D., and William McKee to Board of Directors
5. Teewinot Life Sciences Corporation Licenses Biosynthetic Technology to AMRI for the Production and Sale of the First Commercially Available CBCA Analytical Standard
6. Synthetic Biologics Reports 2015 Year End Operational Highlights and Financial Results
7. Synthetic Biologics Announces Further U.S. Patent Successes Covering SYN-004 Intended for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea
8. Synthetic Biologics to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference
9. Soligenix Announces Initiation of its Pivotal Phase 3 Clinical Trial of SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma
10. Synthetic Biologics to Webcast Microbiome Clinical Program Seminar
11. Global Synthetic Biology Market Expected to Grow With 35% CAGR During 2015 - 2020: P&S Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2018)... ... October 12, 2018 , ... The ... education, innovation and commercialization, celebrates its 50th birthday in New York’s Times Square ... and Electro-Optics (ICALEO) conference. , In celebration of its 50 years, LIA ...
(Date:10/5/2018)... ... 04, 2018 , ... Karius , a life sciences ... at IDWeek™ 2018 the positive results of a study demonstrating that the Karius® ... causative pathogens in patients with infective endocarditis even when blood cultures were negative ...
(Date:10/2/2018)... ... October 02, 2018 , ... ... Solutions™, LLC’s (Locus Bio-Energy) AssurEOR product line was chosen for its advancements in ... Energy Information, honor leading innovations in upstream oil applications that are positively impacting ...
(Date:9/28/2018)... ... September 28, 2018 , ... ... tech innovators, engineers, and scientists from around the world, is excited to announce ... of San Marcos, as the winner of the LabRoots Summer 2018 Textbook Scholarship, ...
Breaking Biology Technology:
(Date:10/5/2018)... ... October 04, 2018 , ... High dose of biotin may cause interference ... as cardiac troponin has serious clinical complications. There is an increasing trend of high ... unknown. , High dose of biotin supplement use may continue to increase due ...
(Date:10/3/2018)... YORK (PRWEB) , ... October 03, 2018 , ... ... in New York City, announces the appointment of healthcare visionary, Jimmy Lee, as ... leader with over 30 years of healthcare industry experience. As a Senior Executive ...
(Date:10/2/2018)... ... ... Stem Cell Innovations (SCI), a global network of professionals working together to ... the pre-sale for their ICO with participants purchasing SCIA Tokens for $0.15 ... stem cell specialists around the world. , SCI (formally Camden RAD, LLC.) ...
Breaking Biology News(10 mins):